Form 8.3 - [Abbvie. Inc]
March 24 2020 - 09:54AM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 23(rd) March 2020
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 67,789,325 4.59068%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 67,789,325 4.59068%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 53,100 66.05
-------------- ----------------------------- -----------------------
Purchase 4,500 64.50
-------------- ----------------------------- -----------------------
Purchase 1,100 64.50
-------------- ----------------------------- -----------------------
Purchase 600 64.50
-------------- ----------------------------- -----------------------
Purchase 2,200 64.50
-------------- ----------------------------- -----------------------
Purchase 3,000 64.50
-------------- ----------------------------- -----------------------
Purchase 300 64.50
-------------- ----------------------------- -----------------------
Purchase 10,700 64.50
-------------- ----------------------------- -----------------------
Purchase 900 64.50
-------------- ----------------------------- -----------------------
Purchase 321 64.27
-------------- ----------------------------- -----------------------
Purchase 1,624 64.50
-------------- ----------------------------- -----------------------
Purchase 1,152 64.50
-------------- ----------------------------- -----------------------
Purchase 520 64.50
-------------- ----------------------------- -----------------------
Purchase 4,400 64.50
-------------- ----------------------------- -----------------------
Purchase 51 64.50
-------------- ----------------------------- -----------------------
Purchase 2,907 64.50
-------------- ----------------------------- -----------------------
Purchase 534 64.50
-------------- ----------------------------- -----------------------
Purchase 564 64.50
-------------- ----------------------------- -----------------------
Sale 297 64.50
-------------- ----------------------------- -----------------------
Sale 2,200 64.50
-------------- ----------------------------- -----------------------
Sale 600 64.50
-------------- ----------------------------- -----------------------
Sale 300 64.50
-------------- ----------------------------- -----------------------
Sale 900 64.50
-------------- ----------------------------- -----------------------
Sale 300 64.14
-------------- ----------------------------- -----------------------
Sale 1,465 64.50
-------------- ----------------------------- -----------------------
Sale 3,556 64.50
-------------- ----------------------------- -----------------------
Sale 373,380 64.50
-------------- ----------------------------- -----------------------
Sale 65,538 64.50
-------------- ----------------------------- -----------------------
Sale 800 64.50
-------------- ----------------------------- -----------------------
Sale 39,564 64.50
-------------- ----------------------------- -----------------------
Sale 3,640 64.50
-------------- ----------------------------- -----------------------
Sale 18,780 64.50
-------------- ----------------------------- -----------------------
Sale 969 64.50
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- -----------------
Date of disclosure 24(th) March 2020
------------------------------------------------------- -----------------
Contact name Lionel Colaco
------------------------------------------------------- -----------------
Telephone number 020 33956098
------------------------------------------------------- -----------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- -----------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- -----------------
(END) Dow Jones Newswires
March 24, 2020 09:39 ET (13:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2023 to Mar 2024